Skip to main content
logo
Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
9.15
+0.18 (2.01%)
Sep 10, 2026, 10:54 AM EDT - Market open

Xilio Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
64.0943.776.34---
Revenue Growth
327.25%589.88%----
Gross Profit
53.343.776.34---
Operating Income
-31.37-41.98-59.65-79.13-89.15-75.04
Net Income
-21.83-35.04-58.24-76.4-88.22-75.8
Earnings Per Share
-3.32-7.73-15.24-38.90-45.09-189.29
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
136.04137.5355.2944.7120.39198.05
Total Debt
6.36.958.1412.5520.0720.74
Net Cash (Debt)
129.74130.5847.1532.15100.32177.32
Net Cash Growth
13.82%176.94%46.64%-67.95%-43.42%-
Net Cash Per Share
19.7228.8212.3416.3751.27442.79

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-60.6-4.99-18.38-68.62-75.72-80.75
Capital Expenditures
-0.67-0.52-0.04-0.49-1.87-1.1
Free Cash Flow
-61.27-5.51-18.41-69.11-77.59-81.85
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
83.16%100.00%100.00%---
Operating Margin
-48.94%-95.92%-940.18%---
Pretax Margin
-34.06%-80.05%-918.05%---
Profit Margin
-34.06%-80.05%-918.05%---
FCF Margin
-95.59%-12.59%-290.26%---

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
0.920.776.62---